Ofatumumab - a highly effective therapy for relapsing-remitting multiple sclerosis available in the first line
2022
Abstract
Monoclonal antibodies are among the fastest growing types of modern biological drugs for a number of different indications. The efficacy of treatment of multiple sclerosis (MS) with monoclonal antibodies directed against the CD20 surface marker of B-lymphocytes has been demonstrated in clinical trials.
Ofatumumab is a fully human anti-CD20 monoclonal antibody approved for the treatment of adult patients with active relapsing-remitting MS. It is the first B-cell therapy intended for subcutaneous application once a month at home.